79561-82-3

Basic information

• Product Name: (R)-N-BOC-4-Bromophenylalanine
• Synonyms: RARECHEM BK PT 0047;(R)-N-BOC-4-BROMOPHENYLALANINE;(R)-3-(4-BROMO-PHENYL)-2-TERT-BUTOXYCARBONYLAMINO-PROPIONIC ACID;N-ALPHA-T-BUTOXYCARBONYL-4-BROMO-D-PHENYLALANINE;N-ALPHA-TERT-BUTYLOXYCARBONYL-D-4-BROMOPHENYLALANINE;BOC-(R)-2-AMINO-3-(4'-BROMOPHENYL)PROPANOIC ACID;BOC-4'-BROMO-D-PHE;BOC-4-BROMO-D-PHENYLALANINE
• CAS NO: 79561-82-3
• Molecular Formula: C14H18BrNO4
• Molecular Weight: 344.2
• Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;Amino Acid Derivatives;a-amino
• Mol File: 79561-82-3.mol

Chemical Properties

• Melting Point: 117.0 to 121.0 °C
• Boiling Point: 475.3 °C at 760 mmHg
• Flash Point: 241.2 °C
• Appearance: off-white crystalline powder
• Density: 1.5311 (rough estimate)
• Vapor Pressure: 7.71E-10mmHg at 25°C
• Refractive Index: 1.6500 (estimate)
• Storage Temp.: Store at RT.
• Solubility: soluble in Methanol
• PKA: 3.83±0.10(Predicted)
• CAS DataBase Reference: (R)-N-BOC-4-Bromophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-BOC-4-Bromophenylalanine(79561-82-3)
• EPA Substance Registry System: (R)-N-BOC-4-Bromophenylalanine(79561-82-3)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 79561-82-3(Hazardous Substances Data)

Usage

Chemical Properties

off-white crystalline powder

InChI:InChI=1/C14H18BrNO4/c1-14(2,3)20-13(19)16-11(12(17)18)8-9-4-6-10(15)7-5-9/h4-7,11H,8H2,1-3H3,(H,16,19)(H,17,18)/p-1/t11-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 14091-15-7 p-bromo-DL-phenylalanine 
• 108540-72-3 4-bromophenylalanine-hydrochloride 
• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 38712-59-3 3-(4-bromophenyl)-2-carbonylpropionic acid 
• 24250-84-8 H-p-BrPhe-OH 
• 1200-07-3 3-(4-bromophenyl)acrylic acid 
• 122839-59-2 (S)-2-amino-3-(4-bromophenyl)propanoic acid hydrochloride 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 

Downstream Products

• 1416469-54-9 tert-butyl [(2R)-3-(4-bromophenyl)-1-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-1-oxopropan-2-yl]carbamate 

Relevant articles and documents

Enantioselective Deaminative Alkylation of Amino Acid Derivatives with Unactivated Olefins

Herein, we report the first Ni-catalyzed enantioselective deaminative alkylation of amino acid and peptide derivatives with unactivated olefins. Key for success was the discovery of a new sterically encumbered bis(oxazoline) ligand backbone, thus offering a de novo technology for accessing enantioenriched sp3-sp3 linkages via sp3 C-N functionalization. Our protocol is distinguished by its broad scope and generality across a wide number of counterparts, even in the context of late-stage functionalization. In addition, an enantioselective deaminative remote hydroalkylation reaction of unactivated internal olefins is within reach, thus providing a useful entry point for forging enantioenriched sp3-sp3 centers at remote sp3 C-H sites.

Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L

Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC50 values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells and, together with two lead analogues, potently inhibited SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range. Reduced antiviral activity was observed in cells overexpressing transmembrane protease, serine 2 (TMPRSS2); however, a synergistic improvement in antiviral activity was achieved when combined with a TMPRSS2 inhibitor. These data highlight the potential of cathepsin L as a COVID-19 drug target as well as the likely need to inhibit multiple routes of viral entry to achieve efficacy.

Preparation method of 2-NH-Boc-3-(3',4'-dimethyl-[1,1'-biphenyl]-4)propionic acid

The invention relates to a preparation method of 2-NH-Boc-3-(3',4'-dimethyl-[1,1'-biphenyl]-4)propionic acid, and mainly solves the technical problem of lack of industrial preparation of the 2-NH-Boc-3-(3',4'-dimethyl-[1,1'-biphenyl]-4)propionic acid at p

CRYSTALLINE(2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF

In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crys

NOVEL PROCESS FOR THE PREPARATION OF SACUBITRIL AND ITS INTERMEDIATES

A process for the preparation of sacubitril and its intermediates is disclosed. By practicing the methods disclosed herein, a solid form of sacubitril may be generated. A crystalline form of sacubitril is also disclosed.

(2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID

In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical

Synthesis of an amidosulfonate-tagged biphenyl phosphine and its application in the Suzuki-Miyaura reaction affording biphenyl-substituted amino acids in water

An amidosulfonate-tagged phosphinobiphenyl, viz triethylammonium 2-(dicyclohexylphosphino)-4′-{[(sulfonatomethyl)amino]carbonyl}biphenyl (3), was prepared in two steps from 2-(dicyclohexylphosphino)biphenyl-4′-carboxylic acid and fully characterized including the crystal structure determination. As a highly polar phosphine ligand, compound 3 was employed in the Pd-catalyzed Suzuki-Miyaura cross-coupling of N-Boc protected 4-bromo and 4-chlorophenylalanine with aromatic boronic acids to afford the corresponding biphenyls in aqueous N,N-dimethylformamide or pure water. The coupling was demonstrated to proceed very well and without the loss of the Boc protecting group when the bromo-substituted substrate is reacted in the presence of 1 mol.% of Pd/3 catalyst in water at 40 °C. Reactions with boronic acids bearing electron-withdrawing substituents and, mainly, those with the less reactive chlorophenylalanine substrate required slightly higher reaction temperature and more catalyst to achieve similar results.

Chemoenzymatic Synthesis of Optically Pure l- and d-Biarylalanines through Biocatalytic Asymmetric Amination and Palladium-Catalyzed Arylation

A chemoenzymatic approach was developed and optimized for the synthesis of a range of N-protected nonnatural l- and d-biarylalanine derivatives. Starting from 4-bromocinnamic acid and 4-bromophenylpyruvic acid using a phenylalanine ammonia lyase (PAL) and an evolved d-amino acid dehydrogenase (DAADH), respectively, both enantiomers of 4-bromophenylalanine were obtained and subsequently coupled with a panel of arylboronic acids to give the target compounds in high yield and optical purity under mild aqueous conditions.

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS

The invention relates to compounds of Formula (I) and its use as a selective dipeptidyl peptidase I inhibitor, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compound